The susceptibility of 28 clinical isolates of Pseudomonas maltophilia to 16 antimicrobial agents was determined in vitro by a standard agar dilution method with inoculum sizes of 104 and 106 CFU. All isolates exhibited multiple drug resistance. Nine isolates were selected for studies of combinations of ciprofloxacin with seven antipseudomonal ,-lactams and three aminoglycosides by a checkerboard agar dilution technique. Synergistic or additive combinations of ciprofloxacin in clinically achievable concentrations were most frequent with meziocillin (89%), followed by cefoperazone (67%), piperacillin (56%), cefsulodin (56%), and ceftazidime (33%), and were infrequent with aztreonam (11%), the aminoglycosides (0 to 14%), or imipenem (0%). Antagonism was not observed in any combination. These data suggest that combinations of ciprofloxacin with these agents may be useful for some nosocomial multiply drug-resistant P. maltophilia infections.
Pseudomonas maltophilia is an important nosocomial pathogen (12) which presents a unique therapeutic challenge because of its tendency to exhibit multiple resistance to aminoglycosides and P-lactams (3, 6, 9, 13) . Furthermore, synergistic activity of aminoglycoside-,-lactam combinations is infrequently observed (3, 9) . We examined the in vitro susceptibility of 28 clinical isolates of P. maltophilia to ciprofloxacin and three other quinolones (norfloxacin, difloxacin, and A-56620), as well as to nine extended-spectrum 1-lactams (carbenicillin, ticarcillin, piperacillin, imipenem, SCH-34343, aztreonam, ceftazidime, cefoperazone, and cefsulodin) and three aminoglycosides (gentamicin, tobramycin, and amikacin), by an agar dilution method. Selected strains were used to test for synergy of ciprofloxacin in combination with other agents by a checkerboard agar dilution technique. Demonstration of synergistic activity in vitro with these antimicrobial combinations may suggest useful therapeutic regimens for these difficult infections in the clinical setting.
A total of 28 P. maltophilia isolates obtained from patients in Vancouver General Hospital were available for study. Sources included sputum (7 isolates), wounds (7 isolates), urine (2 isolates), cerebro spinal fluid (1 isolate), and miscellaneous sites (11 isolates). In vitro susceptibility to each antibiotic was determined by the agar dilution method (1). A Steers replicator was used to deliver a 0.0025-ml inoculum onto the surface of Mueller-Hinton agar (BBL Microbiology Systems) supplemented with calcium (50 mg/liter) and magnesium (25 mg/liter) and containing twofold serial dilutions of the test antibiotics. Unsupplemented Mueller-Hinton agar contained 1.5 mM calcium and 0.7 mM magnesium, as determined by atomic absorption spectrophotometry. The final cation concentrations in the supplemented medium were 2.7 mM calcium and 1.7 mM magnesium. antibiotic which permitted no visible growth. Three reference strains, P. aeruginosa ATCC 27853, Escherichia coli ATCC 25922, and Staphylococcus aureus ATCC 25923, were included in each experiment for quality control. The MICs of each antibiotic for these strains were all within the expected ranges (7, 8) and did not vary more than 1 twofold dilution in 10 separate experiments (95% confidence interval).
Nine isolates with clear resistance to ciprofloxacin (MIC, .4 ,ug/ml) were selected for the combination studies. Combinations of ciprofloxacin with seven extended-spectrum ,-lactams (imipenem, aztreonam, mezlocillin, piperacillin, ceftazidime, cefoperazone, and cefsulodin) and three aminoglycosides (gentamicin, tobramycin, and amikacin) were examined by a two-dimensional checkerboard agar dilution technique. Twofold serial dilutions of antibiotics were prepared to give initial concentrations four times the MICs of the respective antibiotics alone as determined in individual susceptibility tests. Combinations of antibiotics were added with one drug diluted along the x axis and the other drug diluted along the y axis. Thus, for a given range of dilutions every possible combination of drug concentrations was achieved. Plates were inoculated with 104 CFU. per inoculum. In evaluating the combination effects, the ratio of the MIC of one antibiotic in the combination to the MIC of that antibiotic used alone, termed the fractional inhibitory concentration (FIC), was calculated for each antibiotic in each combination, and the FICs were then summated (;FIC). Synergy and antagonism were defined as a minimum IFIC of .0.5 and a maximum XFIC of .4.0, respectively. Additive or indifferent interactions were defined as IFICs in between these two parameters. Interaction indices were noted particularly if they occurred at antibiotic concentrations that can be readily achieved in serum clinically.
The 28 P. maltophilia strains were highly resistant to all P-lactams and aminoglycosides, regardless of the inoculum size (Table 1) . They were also resistant to cipofloxacin, difloxacin, and A-56620 (MIC for 50% of isolates, 2 to 4 j.g/ml; MIC for 90% of isolates, 16 ,ig/ml; range, 0.25 to 16 jig/ml). agents for 50% of isolates were at least four times higher, while the MICs for 90% of isolates were at least two times higher (data not shown). All isolates were highly resistant to norfloxacin. Nine isolates relatively resistant to ciprofloxacin (MIC, .4 ,ug/ml) were selected for combination studies with ciprofloxacin ( Table 1) . Although in vitro synergy (minimum ZFIC, <0.5) was most frequent with ceftazidime (100% of isolates), followed by piperacillin, cefoperazone, cefsulodin, and aztreonam (67% each), mezlocillin plus ciprofloxacin was the most active combination at clinically achievable concentrations (either synergistic or additive for 89% of isolates), followed by cefoperazone (67%), piperacillin (56%), cefsulodin (56%), and ceftazidime (33%) plus ciprofloxacin (Table 2 ). For each antibiotic combination, the interaction indices at each antibiotic concentration for all isolates were tabulated. Synergistic interactions (IFIC, <0.5) were most frequently observed with cefsulodin (27% of total indices) and ceftazidime (23%), followed by mezlocillin (19%), aztreonam (18%), cefoperazone (14%), piperacillin (13%), the aminoglycosides (4 to 8%), and imipenem (4%). These were well above the 1% frequency which Haller considered as expected "background activity" due to methodological variations of the checkerboard assay (10) . Antagonism (maximum IFIC, >4.0) was not observed in any combination, although several antibiotic combinations yielded maximum IFICs of >2.0 (Table 1) .
The in vitro susceptibility of P. maltophilia recorded here was similar to that previously reported by Felegie et al. (9) and several others (3, 6, 13, 15) , all of whom demonstrated the multiple resistance of these organisms to antipseudomonal ,-lactams and aminoglycosides. Our data indicated that ciprofloxacin and the quinolones from Abbott Laboratories (difloxacin and A-56620) were also only moderately active. These results were similar to those of Kelley et al. (14) and several others (4-6, 13), even though different methods of susceptibility testing were used by these authors. It has been reported by several investigators that the cation concentration and type of medium used for susceptibility testing may greatly influence the in vitro activity of 3-lactams, aminoglycosides, and quinolones (1, 2, 9, 11, 17). Although the National Committee for Clinical Laboratory Standards specifically states that Mueller-Hinton agar should not be supplemented with cations, we feel that it is prudent to routinely determine the calcium and magnesium concentrations of the medium to be used to appropriately assess the need for supplementation, since variations in media between lots and from different manufacturers do exist (1) . The (3, 9, 10) . Apart from ciprofloxacin combinations demonstrated in the present study, the frequent occurrence of synergistic interactions against P. maltophilia has also been observed for combinations containing trimethoprim-sulfamethoxazole and carbencillin with or without rifampin (9, 16) and for triple combinations of gentamicin, carbenicillin, and rifampin (16) . The clinical relevance of these in vitro interactions will need to be confirmed by in vivo investigations of therapeutic efficacy. Nevertheless, our data indicate that ciprofloxacin does not appear to antagonize the activity of several extended-spectrum P-lactams and aminoglycosides, and combinations of ciprofloxacin with these agents may prove useful for the management of difficult infections caused by multiply drugresistant P. maltophilia.
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